Skip to main content
SpringerLink
Log in

Drug Resistance to Antiestrogens

  • Chapter
Hormone Therapy in Breast and Prostate Cancer

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 331 Accesses

Abstract

Tamoxifen (Nolvadex®) (Fig. 1), a nonsteroidal antiestrogen, is the endocrine treatment of choice for all stages of breast cancer. The drug has ten million women years of clinical experience and is described by the World Health Organization (WHO) as an essential treatment for breast cancer. The clinical pharmacology of tamoxifen has been studied in great detail because it is continuing to be tested as a preventive for breast cancer in high-risk women (1). This strategy is based on three important facts. Firstly, tamoxifen prevents rat mammary carcinogenesis (2,3). Secondly, tamoxifen reduces the incidence of contralateral breast cancer (4) and thirdly, when the preliminary studies were started in 1986 (5), tamoxifen was believed to have a low incidence of side effects (6).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jordan VC. Current view of the use of tamoxifen for the treatment and prevention of breast cancer. Gaddum Memorial Lecture. Br J Pharmacol 1993; 110:507–517.

    CAS  PubMed  Google Scholar 

  2. Jordan VC. Antitumour activity of the antioestrogen ICI46,474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. J Steroid Biochem 1974; 5:354.

    Article  Google Scholar 

  3. Jordan VC. Effect of tamoxifen (ICI46,474) on initiation and growth of DMBA-induced rat mammary carcinoma. Eur J Cancer 1976; 12:419–424.

    CAS  PubMed  Google Scholar 

  4. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet 1985; 2:282.

    Article  CAS  PubMed  Google Scholar 

  5. Powles TJ, Hardy JR, Ashley SE, Farrington GM. A pilot trial to evaluate the acute toxicity and feasibility to tamoxifen for prevention of breast cancer. Br J Cancer 1989; 60:126–133.

    CAS  PubMed  Google Scholar 

  6. Furr BJA, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984; 25:127–205.

    Article  CAS  PubMed  Google Scholar 

  7. Jordan VC, Phelps E, Lindgren JU. Effects of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 1987; 10:31–35.

    Article  CAS  PubMed  Google Scholar 

  8. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326:852–856.

    Article  CAS  PubMed  Google Scholar 

  9. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988; 48:812–815.

    CAS  PubMed  Google Scholar 

  10. Assikis VJ, Neven P, Jordan VC, Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 1996; 32A:1464–1476.

    Article  CAS  PubMed  Google Scholar 

  11. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer. English Cain Memorial Lecture. Cancer Res 1990; 50:4177–4189.

    CAS  PubMed  Google Scholar 

  12. Black LJ, Jones CD, Falcone JF. Antagonism of estrogen action with a new benzothiophenederived derived antiestrogen. Life Sci 1983; 32:1031–1036.

    Article  CAS  PubMed  Google Scholar 

  13. Gottardis MM, Jordan VC. The antitumor action of keoxifene (raloxifene) and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 1987; 47:4020–4024.

    CAS  PubMed  Google Scholar 

  14. Gottardis MM, Ricchio MD, Satyaswaroop PG, Jordan VC. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res 1990; 50:3189–3192.

    CAS  PubMed  Google Scholar 

  15. Rose C, Thorpe SM, Andersen KW, Pedersen BV. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1985; i:16–19.

    Article  Google Scholar 

  16. Ribeiro G, Swindell R. The Christie Hospital Adjuvant Tamoxifen Trial: status at 10 years. Br J Cancer 1988; 57:601–603.

    CAS  PubMed  Google Scholar 

  17. Hubay CA, Pearson OH, Marshall JS, Stellato TA, Rhodes RS. Adjuvant therapy of stage II breast cancer: 48 month follow-up of a prospective randomized clinical trial. Breast Cancer Res Treat 1981; 1:77–82.

    Article  CAS  PubMed  Google Scholar 

  18. Jordan VC. Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen treatment as a potential adjuvant therapy. Rev Endo Rel Cancer 1978; (October Suppl):49–55.

    Google Scholar 

  19. Jordan VC, Dix CJ, Allen KE. The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer, in (Salmon SE, Jones SE, eds.) Adjuvant Therapy of Cancer II. Grune & Stratton Inc., Orlando, 1979, pp 19–26.

    Google Scholar 

  20. Jordan VC, Allen KE. Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 1980; 16:239–251.

    CAS  PubMed  Google Scholar 

  21. Jordan VC. Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications. Breast Cancer Res Treat 1983; 3(Suppl):73–86.

    Article  CAS  Google Scholar 

  22. Baum M, Brinkley DM, Dossett JA, McPherson K, Patterson JS, Rubens RD, et al. Improved survival amongst patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 1983; ii:450.

    Article  Google Scholar 

  23. Scottish Cancer Trials Office. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 1987; ii:171–175.

    Google Scholar 

  24. Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339:1–15, 71–85.

    Google Scholar 

  25. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996; 88:1543–9.

    Google Scholar 

  26. Osborne CK, Hobbs K, Clark GM. Effects of estrogens and anti-estrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 1985; 45:584–590.

    CAS  PubMed  Google Scholar 

  27. Gottardis MM, Robinson, SP, Jordan VC. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 1988; 20:311–314

    Article  Google Scholar 

  28. Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 1988; 48:5183–5187.

    CAS  PubMed  Google Scholar 

  29. Gottardis MM, Wagner RJ, Borden EC, Jordan VC. Differential ability of antiestrogens to stimulate breast cancer cell line (MCF-7) growth in vivo and in vitro. Cancer Res 1989; 49:4765–4769.

    CAS  PubMed  Google Scholar 

  30. Wolf DM, Langan-Fahey SM, Parker CJ, McCague R, Jordan VC. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth using nonisomerizable analogs of tamoxifen and metabolites. J Natl Cancer Inst 1993; 85:806–812.

    Article  CAS  PubMed  Google Scholar 

  31. Welshons WV, Jordan VC. Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur J Cancer Clin Oncol 1987; 23:1935–1939.

    Article  CAS  PubMed  Google Scholar 

  32. Pink JJ, Jiang S-Y, Fritsch M, Jordan VC. An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein. Cancer Res 1995; 55:2583–2590.

    CAS  PubMed  Google Scholar 

  33. Jordan VC. The control of hormone-dependent breast cancer growth: are we talking about estrogen alone?. Eur J Cancer Clin Oncol 1988; 24:1245–1248.

    Article  CAS  PubMed  Google Scholar 

  34. Wakeling AE. Therapeutic potential of pure antiestrogens in the treatment of breast cancer. J Steroid Biochem Mol Biol 1990; 37:771–775.

    Article  CAS  PubMed  Google Scholar 

  35. Gottardis MM, Jiang SY, Jeng MH, Jordan VC. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 1989; 49:4090–4093.

    CAS  PubMed  Google Scholar 

  36. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human cancer. J Natl Cancer Inst 1995; 87:746–750.

    Article  CAS  PubMed  Google Scholar 

  37. Howell A, DeFriend D, Robertson H, Blamey R, Walton P. Response to a specific antiestrogen (ICI 182,780) in tamoxifen-resistant breast cancer. Lancet 1995; 345:29–30.

    Article  CAS  PubMed  Google Scholar 

  38. Howell A, DeFriend DJ, Robertson JF, Blamey RW, Anderson L, Anderson E, et al. Pharmacokinetics, pharmacological and antitumour effects of the specific anti-oestrogen ICI 182,780 in women with advanced breast cancer. Br J Cancer 1996; 74:300–306.

    CAS  PubMed  Google Scholar 

  39. Satyaswaroop PG, Zaino RJ, Mortel R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 1984; 44:4006–4010.

    CAS  PubMed  Google Scholar 

  40. Fornander T, Rutqvist LE, Cedermark B, Glass U, Mattsson A, Silfverswaard C, et al. Adjuvant tamoxifen in early breast cancer: ocurrence of new primary cancers. Lancet 1989; i:117–120.

    Article  Google Scholar 

  41. Assikis VJ, Jordan VC. Gynecological effects of tamoxifen and the association, with endometrial cancer. Int J Gynaecol Obstet 1995; 49:241–257.

    Article  CAS  PubMed  Google Scholar 

  42. Jordan VC, Morrow M. Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur J Cancer 1994; 30A:1714–1721.

    Article  CAS  PubMed  Google Scholar 

  43. Phillips DH, Carmichael PL, Hewer A, Cole KJ, Hardcastle IR Poon GK, Deogh A. Activation of tamoxifen and its metabolite alpha-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes. Carcinogenesis 1996; 17:89–94.

    Article  CAS  PubMed  Google Scholar 

  44. Martin EA, Rich KJ, White IN, Woods KL, Powles TH, Smith LL. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 1995; 16:1651–1654.

    Article  CAS  PubMed  Google Scholar 

  45. Carmichael PL, Ugwumadu AH, Neven P, Herwe AH, Poon GK, Phillips DH. Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 1996; 56:1475–1479.

    CAS  PubMed  Google Scholar 

  46. Hemminki K, Rajaniemi H, Lindahl B, Moberger B. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res 1996; 56:4374.

    CAS  PubMed  Google Scholar 

  47. International Agency for Research on Cancer (IARC) Tamoxifen. IARC Monogr Eval Carcinog Risks Hum 1996; 66:253–365. (http://www.iarc.fr/preleases/111e.htm)

  48. Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 1995; 13:2556–2566.

    CAS  PubMed  Google Scholar 

  49. Vogel CL, Shemano I, Schoenfelder J, Gams RA, Green MR. Multicenter phase II efficacy trial of toremifene in tamoxifen refractory patients with advanced breast cancer. J Clin Oncol 1993; 11:345–350.

    CAS  PubMed  Google Scholar 

  50. Stenbygaard LE, Herrstedt J, Thomsen JF, Svendsen KR, Engelholm SA, Dombernowsky P. Toremifene and tamoxifen in advanced breast cancer- a double-blind cross-over trial. Breast Cancer Res Treat 1993; 25:57–63.

    Article  CAS  PubMed  Google Scholar 

  51. Merimsky O, Inbar M, Kovner F, Ohaitchik S. Adjuvant tamoxifen: 5 year control of dormant disease. Eur J Cancer 1996; 32A:174.

    Article  CAS  PubMed  Google Scholar 

  52. Ebbs SR, Roberts J, Baum M. Response to toremifene (Fc-1157a) therapy in tamoxifen failed patients with breast cancer. Preliminary communication. J Steroid Biochem 1990; 36:239.

    Article  CAS  PubMed  Google Scholar 

  53. Hard GC, Iatropoulos MJ, Jordan K, Radi K, Kaltenberg OP, Imondi AR, Williams GM. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res 1993; 53:4534–4541.

    CAS  PubMed  Google Scholar 

  54. Jensen EV, Jacobson HI. Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 1962; 18:378–414.

    Google Scholar 

  55. Gorski J, Toft D, Shyamala G, Smith D, Notides A. Hormone receptors: studies on the interaction of estrogen with the uterus. Recent Prog Horm Res 1968; 24:45–80.

    CAS  PubMed  Google Scholar 

  56. Jensen EV, Block GE, Smith S, Kyser K, PeSombre ER. Estrogen receptors and breast cancer response to adrenalectomy, in Prediction of Response in Cancer Therapy Monogr Natl Cancer Inst. (Hall TC, ed). Washington DC, 1971; 34:55–70.

    Google Scholar 

  57. Jordan VC. William L. McGuire Memorial Lecture. “Studies on the estrogen receptor in breast cancer”: 20 years as a target for the treatment and prevention of breast cancer. Breast Cancer Res Treat 1995; 36:267–285.

    Article  CAS  PubMed  Google Scholar 

  58. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engstom O, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (Lond) 1997; 389:753–758.

    Article  CAS  Google Scholar 

  59. Danielian PS, White R, Lees JA, Parker MG. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J 1992; 11:1025–1033.

    CAS  PubMed  Google Scholar 

  60. Tzukerman MT, Esty A, Santiso-Mere D, Santiso-Mere D, Danelian D, Parker MG, et al. Human estrogen receptor transactivational capacity is determined by both cellular and pro- moter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 1994; 18:21–30.

    Article  Google Scholar 

  61. Berry M, Metzger D, Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 1990; 9:2811–2818.

    CAS  PubMed  Google Scholar 

  62. Jordan VC. Biochemical pharmacology of antiestrogen action. Pharmacol Rev 1984; 36:245–276.

    CAS  PubMed  Google Scholar 

  63. Lednicer D, Lyster SC, Aspergren BD, Duncan GW. Mammalian antifertility agents. III. 1- Aryl-2-phenyl-1,2,3,4-tetrahydro-1-naphthols, 1-anyl-2-phenyl-3,4-dihydronaphthalenes and their derivatives. J Med Chem 1966; 9:172–176.

    Article  CAS  PubMed  Google Scholar 

  64. Clark ER, Jordan VC. Oestrogenic, antiestrogenic and antifertility properties of a series of compounds related to ethamoxytriphetol (MER-25). Br J Pharmacol 1976; 57:487–493.

    CAS  PubMed  Google Scholar 

  65. Robertson DW, Katzenellenbogen JA, Hayes JR, Katzenellenbogen BS. Antiestrogen basicityactivity relationships: A comparison of the estrogen receptor binding and antituterotrophic potencies of several analogues of (Z)-1,2-diphenyl-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1- butene (Tamoxifen, Nolvadex) having altered basicity. J Med Chem 1982; 25:167–171.

    Article  CAS  PubMed  Google Scholar 

  66. Jordan VC, Gosden B. Importance of the alkylaminoethoxy side chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the immature rat uterus. Mol Cell Endocrinol 1982; 27:291–306.

    Article  CAS  PubMed  Google Scholar 

  67. Tate AC, Greene GL, DeSombre ER, DeSombre ER, Jensen EV, Jordan VC. Differences between estrogen and antiestrogen-estrogen receptor complexes identified with an antibody raised against the estrogen receptor, Cancer Res 1984; 44:1012–1018.

    CAS  PubMed  Google Scholar 

  68. Lieberman ME, Gorski J, Jordan VC. An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro. J Biol Chem 1983; 258:4741–4745.

    CAS  PubMed  Google Scholar 

  69. Mahfoudi A, Poulet E, Dauvois S, et al. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA 1995; 92:4206–4210.

    Article  CAS  PubMed  Google Scholar 

  70. Bilimoria MM, Assikis VJ, Muenzner HD, Wolf DM, Satyaswaroop PG, Jordan VC. An analysis of tamoxifen-stimulated human carcinomas for mutations in the AF-2 region of the estrogen receptor. J Steroid Biochem Mol Biol 1996; 58:479–488.

    Article  CAS  PubMed  Google Scholar 

  71. Wolf DM, Jordan VC. Characterization of tamoxifen stimulated MCF-7 tumor variant grown in athymic mice. Breast Cancer Res Treat 1994; 31:117–127.

    Article  CAS  PubMed  Google Scholar 

  72. Wolf DM, Jordan VC. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat 1994; 31:129–138.

    Article  CAS  PubMed  Google Scholar 

  73. Jiang SY, Jordan VC. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 1992; 84:580–591.

    Article  CAS  PubMed  Google Scholar 

  74. Jiang SY, Parker CJ, Jordan VC. A model to describe how a point mutation of the estrogen receptor alters the structure function relationship of antiestrogens. Breast Cancer Res Treat 1993; 26:139–148.

    Article  CAS  PubMed  Google Scholar 

  75. Jiang SY, Langan-Fahey SM, Stella A, McCague R, Jordan VC. Point mutation of the estrogen receptor (ER) in the ligand binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing cDNAs for ER. Mol Endocrinol 1992; 6:2167–2174.

    Article  CAS  PubMed  Google Scholar 

  76. Tora L, Mullick A, Metzger D, Ponglikitmongkol M. The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO J 1989; 8:1981–1986.

    CAS  PubMed  Google Scholar 

  77. Catherino WH, Wolf DM, Jordan VC. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analogue. Mol Endocrinol 1995; 9:1053–1063.

    Article  CAS  PubMed  Google Scholar 

  78. Catherino WH, Jordan VC. Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. Cancer Lett 1995; 92:39–47.

    Article  CAS  PubMed  Google Scholar 

  79. Jeng M-H, Jiang S-Y, Jordan VC. Paradoxical regulation of estrogen-dependent growth factor gene expression in estrogen receptor (ER)-negative human breast cancer cells stably expressing ER. Cancer Lett 1994; 82:123–128.

    Article  CAS  PubMed  Google Scholar 

  80. Jordan VC, Jiang SY, Jeng MH, Catherino WH, Wolf DM. Regulation of cell growth with the transfected estrogen-receptor gene, in Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects (Motta M, Serio M eds.). Elsevier Science BV, Amsterdam, 1994, pp 243–248.

    Google Scholar 

  81. Levenson AS, Catherino WH, Jordan VC. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J Steroid Biochem Mol Biol 1997; 60:261–268.

    Article  CAS  PubMed  Google Scholar 

  82. Levenson AS, Tonetti DA, Jordan VC. The estrogen-like effect of 4-hydroxytamoxifen on transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor. Br J Cancer 1998; 77:1812–1819.

    CAS  PubMed  Google Scholar 

  83. McDonnell DP, Clemm DL, Hermann T, Hermann T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 1995; 9:659–669.

    Article  CAS  PubMed  Google Scholar 

  84. Jordan VC: Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 1993; 110:507–517.

    CAS  PubMed  Google Scholar 

  85. Jordan VC, Phelps E, Lindgren JU. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 1987; 10:31–35.

    Article  CAS  PubMed  Google Scholar 

  86. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337:1641–1647.

    Article  CAS  PubMed  Google Scholar 

  87. Jordan VC, MacGregor JI, Tonetti DA. Tamoxifen: from breast cancer therapy to the design of a postmenopausal prevention maintenance therapy. Osteoporos Int 1997; 7(S1):S52–57.

    Article  PubMed  Google Scholar 

  88. Jordan VC. Tamoxifen: the herald of a new era of preventive therapeutics. J Natl Cancer Inst 1997; 89:747–749.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical Program, Chicago, IL

    Ruth M. O’Regan

  2. Northwestern University Medical Program, Chicago, IL

    Anait S. Levenson, Gale M. England, Kathy A. Yao & Henry D. Muenzner

  3. Second Department of Surgery, Gunma University School of Medicine, Maebashi, Japan

    Hiroyuki Takei

  4. Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

    V. Craig Jordan

Authors
  1. Ruth M. O’Regan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anait S. Levenson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gale M. England
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kathy A. Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Henry D. Muenzner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroyuki Takei
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. V. Craig Jordan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lombardi Comprehensive Cancer Center, Georgetown University, 3970 Reservoir Rd. NW Research Bldg. E501, Washington, DC, 20057, USA

    V. Craig Jordan

  2. AstraZeneca Pharmaceuticals Zeneca Pharmaceutical, Alderly Park, Alderly House, Macclesfield, SK 10 4TF, UK

    Barrington J.A. Furr

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

O’Regan, R.M. et al. (2009). Drug Resistance to Antiestrogens. In: Jordan, V.C., Furr, B.J. (eds) Hormone Therapy in Breast and Prostate Cancer. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59259-152-7_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-152-7_3

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-471-5

  • Online ISBN: 978-1-59259-152-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation